Mark Freedman, HBSc, MSc, MD, discusses ocrelizumab
at ACTRIMS in New Orleans

2.28.16 ACTRIMS, New Orleanse, LA

Mark Freedman, HBSc, MSc, MD, discusses ocrelizumab
at ACTRIMS in New Orleans

2.28.16 ACTRIMS, New Orleanse, LA

As the first medication designed to treat primary progressive multiple sclerosis moves closer to the market there are still many questions about how effective it will be and what other treatment options may look like in the future.

Mark Freedman, HBSc, MSc, MD, from the University of Ottawa discussed some of the many challenges doctors are facing when treating these patients and what ocrelizumab could mean in this fight during the annual meeting of ACTRIMS in New Orleans. Freedman said an additional challenge for patients is whether the medication will work on patients with both primary and secondary progressive multiple sclerosis or whether it will be more effective in one over the other.

 

To help us continue raising awareness for MS please DONATE HERE